Cryoport, Inc. · NASDAQ:CYRX
Cryoport — Merger or Acquisition (August 2020)
15 slides from Cryoport's merger presentation, Aug 25, 2020
Slide 1: Cryoport to acquire MVE Biological Solutions
@2 cryoport’ SCIENCE. LOGISTICS. CERTAINTY. Cryoport to acquire MVE Biological Solutions
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation and statements made orally during tis presentation are not purely historical, including statements regarding Cryopor’s intentions, nopes, belies, ‘expectations, representations pr0}ections, plans or predictions ofthe futur ae forware ooking
Slide 3: Strategic Rationale of Acquisition
fe} Strategic Rationale of Acquisition MVE BIOLOGICAL SOLUTIONS — ADDING STRENGTH AND REACH——————---——* b= QA oe | eee ee) eee | ee camacees | Giecercte | tromesame | Remeoecrs | Shana fighest quality and one tee ory oon ‘Yacuum insulted fxpectedto heseoely “supporting Penh growth ic freezer ace oe
Slide 4: Transaction Overview
oO Transaction Overview Acquisition Price Path to Completion Total cash consideration of $320MM $275MNM investment by Blackstone — $25MM of common stock — $250MM of preferred equity $45MM from cash on balance sheet Customary closing conditions including: — Receipt of applicable regulatory approvals
Slide 5: MVE Biological Solutions Overview
oO MVE Biological Solutions Overview ae = Gi ---~- a irate —_— sone coe “MVE Blologieal Sotuion the leasing manufacturer of eryogeni ie sciences equipment, proving freezers, dwar ond ‘equpmert used or storage and vtaton rans + Tiee primary locations ~ Bat Ground, GA ~ New Prague, uN ~ Chengdu, china
Slide 6: MVE — A Trusted Partner to Life Sciences
fe} MVE — A Trusted Partner to Life Sciences A GLOBAL LEADER OF CRYOGENIC SHIPPING AND STORAGE SOLUTIONS MVE BIOLOGICAL ALUMINUM SOLUTIONS MVE BIOLOGICAL STAINLESS STEEL SOLUTIONS Vapor & Doble | cr-soact- | crye-cube Shippers | 250 Blood Bag Vapor Shippers cryoport” ‘THE INDUSTRY'S MOST TRUSTED PRO
Slide 7: Cryoport — A Trusted Partner to Life Sciences
Oo Cryoport — A Trusted Partner to Life Sciences GLOBAL LEADER OF TEMPERATURE-CONTROLLED SUPPLY CHAIN SOLUTIONS AUS kal $ 491 68% ~44% If ~69% ~$38MM coettn | Aa) | SRUee @ i Ps inss| & ti 4 265+ 325,000+ / 100+ 8 mae ne soma a RST ere recom or coun sien Locees sourone ron eseanerony-emeema Lin scen
Slide 8: Expanding Our Addressable Market
oO Expanding Our Addressable Market Cell & Gene Therapy Growing 35 — 40%+ eee ees 1,078 1,001+ $10.7Bn 23 tl Gat Ieper ace Tel iba peor coWo9 Sn israel rnc Raves vee peas onghiosy Sp aL a Gene THERAPY MARKET——————+ The acquisitions of CryoPDP and fm MVE Biological Solutions expands Cryoport’s addres
Slide 9: Attractive High-Growth Regenerative Medicine Market
Attractive High-Growth Regenerative Medicine Market Driving Demand Patients Treated per Year in Trials of Commercially Approved Thertioe Ponroved by Sonata Theor non e e chon « x ° = = ser ine we oe ey tna = a ont nett cis rata we rama ve sey nt ose aa ‘aw ppl oa Pb epantonesnby ney eet ney eros may
Slide 10: Attractive High-Growth Regenerative Medicine Market
Attractive High-Growth Regenerative Medicine Market Driving Demand ‘Therapies Approved ‘Addressable Market for Cryogenic Shipping ' ne neraples requring eryogenc shipping) approved by FOA am » ‘Therapies to be approved by the FDA and requiring ‘eryogenic shipping x 0 Revenue per commercial drug (Ran
Slide 11: Accelerating Growth with Acquisitions
fo) Accelerating Growth with Acquisitions Proforma Revenue -Trailing Twelve Months as of 6/30/20 $167 su
Slide 12: Amplifying Cryoport's Strength across the Life Sciences Landscape
Amplifying Cryoport’s Strength across the Life Sciences Landscape cryoport® | CRYOGENE® +. CLYOPDP* + MVE Biological Solutions acysoatconeany a cryoport company V CryoPDP: 3%targest specialty global ogists player Market Leader ep palin ommobiiais V MVE: Aleadingmanufacturr of ryogenie equipment 7 Cr
Slide 13: Partnership with Blackstone
(eo) Partnership with Blackstone Blackstone (BX) is one of the most active healthcare investors globally and will provide Cryoport with an unmatched network to support the growing demand in Cell and Gene Therapy. Global Platform Commitment to Healthcare Largest ‘Atemative Asset Management Firm inthe
Slide 14: Operating Holding Structure — Expanding Tools and Solutions for the Life Sciences
Operating Holding Structure — Expanding Tools and Solutions for the Life Sciences Cryport, Inc. (NASDAQ: CYRX) Incas a aailaeliatal -@.cryoport company CrvoppP® | cryoport” CRYOGENE® SaaS he AU Reet
Slide 15: Science. Logistics. Certainty.
Science. Logistics. Certainty. Thank you!